logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
M

Min‐Hee Ryu

Asan Medical Center

60H指数
520论文数
2.0W被引数
收录论文 165
发表时间
logo
Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study帕博利珠单抗联合化疗作为HER2阴性晚期胃或胃食管结合部腺癌的一线治疗：来自随机III期KEYNOTE-859研究的4.5年随访
errESMO Open
IF8.3
err2026-09-01
err0
PREAI
errRha, S. Y.; Wyrwicz, L. S.; Yanez, P.; Bai, Y.; Ryu, M-H; Lee, J.; Rivera, F.; Alves, G. Vasconcelos; Garrido, M.; Shiu, K-K; Fernandez, M. Gonzalez; Li, J.; Lowery, M. A.; Cil, T.; Cruz, F. Melo; Oh, D-Y; Wang, A.; Leconte, P.; Qin, S.
err分享
err收藏
Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapynivolumab联合化疗治疗的胃癌患者中恶性腹水的存在与生存结局之间的关系
errInternational Journal of Cancer
IF4.7
err2026-01-28
err0
PREAI
errYuna Lee; Hyung-Don Kim; Hyungeun Lee; Jaewon Hyung; Meesun Moon; Jungeun Ma; Min-Hee Ryu
err分享
err收藏
Risk factors and clinical outcomes associated with leptomeningeal carcinomatosis in gastric cancer与胃癌软脑膜癌病相关的危险因素和临床结局
errGastric Cancer
IF5.1
err2026-01-03
err0
PREAI
errSeong-Eun Kim; Hyung-Don Kim; Meesun Moon; Jaewon Hyung; Jungeun Ma; Hyungeun Lee; Min-Hee Ryu
err分享
err收藏
Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer更正：一项多中心 Ib/II 期研究，评估度鲁木单抗和 Tremelimumab 联合多西他赛在生物标志物选择的转移性胃癌患者中的二线治疗。
errBritish Journal of Cancer
IF6.8
err2025-11-11
err0
PREAI
errKeun-Wook Lee; Dae Young Zang; Hyung-Don Kim; Jin-Won Kim; Bum Jun Kim; Yoon-Koo Kang; Min-Hee Ryu; Hark Kyun Kim
err分享
err收藏
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial一线帕博利珠单抗联合化疗治疗HER2阴性胃或胃食管结合部腺癌：来自随机III期KEYNOTE-859试验的健康相关生活质量
errEuropean Journal of Cancer
IF7.1
err2025-09-20
err0
PREAI
errMaeve A. Lowery; Lucjan S. Wyrwicz; Do-Youn Oh; Kai-Keen Shiu; Patricio Yañez; Yuxian Bai; Min-Hee Ryu; Jeeyun Lee; Fernando Rivera; Gustavo Vasconcelos Alves; Marcelo Garrido; Manuel González Fernández; Jin Li; Timuçin Çil; Felipe Melo Cruz; Shukui Qin; Yanfen Guan; Adriana Valderrama; Sonal Bordia; Sun Young Rha
err分享
err收藏
Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer同源重组相关基因突变在纳武利尤单抗联合化疗一线治疗胃癌中的预后价值
errGastric Cancer
IF5.1
err2025-07-28
err0
PREAI
errYuna Lee; Hyung-Don Kim; Sun Young Lee; Hyungeun Lee; Jaewon Hyung; Meesun Moon; Jinho Shin; Young Soo Park; Tae Won Kim; Min-Hee Ryu
err分享
err收藏
Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer更正：一项多中心 Ib/II 期研究，评估度伐利尤单抗和特瑞普利单抗联合紫杉醇在生物标志物选择的转移性胃癌患者中的二线治疗。
errBritish Journal of Cancer
IF6.8
err2025-06-20
err0
PREAI
errKeun-Wook Lee; Da Young Zang; Hyung-Don Kim; Jin-Won Kim; Bum Jun Kim; Yoon-Koo Kang; Min-Hee Ryu; Hark Kyun Kim
err分享
err收藏
Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer多中心Ib/II期研究：在生物标志物选择的转移性胃癌患者中，二线使用durvalumab和tremelimumab联合paclitaxel的疗效。
errBRITISH JOURNAL OF CANCER
IF6.8
err2025-05-21
err0
PREAI
errLee, Keun Wook; Zang, Da Young; Kim, Hyung-Don; Kim, Jin-Won; Kim, Bum Jun; Kang, Yoon-Koo; Ryu, Min-Hee; Kim, Hark Kyun
err分享
err收藏
Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapyEBV阳性在应用一线纳武利尤单抗联合化疗治疗的胃癌患者中的预测价值
errGASTRIC CANCER
IF5.1
err2025-04-28
err0
PREAI
errHyung-Don Kim; So-Yeon Kim; Hyungeun Lee; Yuna Lee; Jaewon Hyung; Meesun Moon; Jinho Shin; Young Soo Park; Min-Hee Ryu
err分享
err收藏
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCCHIMALAYA研究五-year总体生存率更新：曲美木单抗联合度伐利尤单抗治疗不可切除性HCC
errJournal of Hepatology
IF33
err2025-04-11
err0
errOAAI
errLorenza Rimassa; Stephen L. Chan; Bruno Sangro; George Lau; Masatoshi Kudo; Maria Reig; Valeriy Breder; Min-Hee Ryu; Yuriy Ostapenko; Wattana Sukeepaisarnjaroen; Maria Varela; David Tougeron; Oxana V. Crysler; Mohamed Bouattour; Tu Van Dao; Vincent C. Tam; Adilson Faccio; Junji Furuse; Long-Bin Jeng; Yoon Koo Kang; Robin K. Kelley; Michael J. Paskow; Di Ran; Ioannis Xynos; John F. Kurland; Alejandra Negro; Ghassan K. Abou-Alfa
err分享
err收藏
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer纤维母细胞生长因子受体2b的低阳性率与胃癌中异质性表达相关
errGASTRIC CANCER
IF5.1
err2025-04-11
err0
PREAI
errLee, Heonwoo; Ryu, Min-Hee; Lee, In-Seob; Ahn, Ji Yong; Lee, Jeong Hoon; Lee, Hyungeun; Kim, Hyung-Don; Park, Young Soo
err分享
err收藏
Updated efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 studySHR-A1811，一种抗HER2抗体药物偶联物，在HER2表达或突变的重度预治晚期实体瘤中的更新疗效与安全性：一项全球、多中心、I期研究
errBREAST
IF7.9
err2025-02-01
err0
errOAAI
errYao, H.; Yan, M.; Tong, Z.; Wu, X.; Yin, Y.; Ryu, M. -h.; Park, J. J.; Dai, T.; Zhao, Y.; Kim, J. H.; Wang, S.; Zhong, Y.; Voskoboynik, M.; Zhang, J.; Kaubisch, A.; Liu, C.; Chen, Y.; Im, S. -a.; Wu, L.; Liu, Y.; Ganju, V.; Barve, M.; Li, H.; Yao, G.; Bao, L.; Teng, Y.; Qian, J.; Zhou, H.; Zhao, J.; Zhao, K.; Shen, Y.; Rong, S.; Zhu, X.; Song, E.
err分享
err收藏
Advancing Systemic Therapy in Gastric Cancer: Key Updates From the Korean Practice Guidelines for Gastric Cancer 2024
errgastric cancer
IF3.8
err2025-01-01
err0
PREAI
errRyu, Min-Hee; Ryu, Keun Won
err分享
err收藏
KEYNOTE-859 update: Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancerKEYNOTE-859更新：帕博利珠单抗联合化疗治疗晚期HER2阴性胃或胃食管结合部（G/GEJ）癌
errANNALS OF ONCOLOGY
IF65.4
err2024-12-01
err0
PREAI
errRyu, M. H.; Rha, S. Y.; Wyrwicz, L. S.; Weber, P. E. Yanez; Bai, Y.; Lee, J.; Herrero, F. Rivera; Alves, G. V.; Garrido, M.; Shiu, K-K.; Gonzalez Fernandez, M.; Li, J.; Lowery, M. A.; Cil, T.; Cruz, F.; Oh, D-Y.; Yin, L.; Bordia, S.; Bhagia, P.; Qin, S.
err分享
err收藏
Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression基于claudin 18.2表达的一线nivolumab加化疗治疗胃癌患者的生存结局
errGASTRIC CANCER
IF5.1
err2024-11-11
err0
PREAI
errKim, Hyung-Don; Shin, Jinho; Hyung, Jaewon; Lee, Hyungeun; Moon, Meesun; Ma, Jeongeun; Park, Young Soo; Ryu, Min-Hee
err分享
err收藏
Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs)
errBMC CANCER
IF3.4
err2024-10-08
err0
errOAAI
errKim, Sejin; Kim, Hyung-Don; Kim, Eo Jin; Ryu, Min-Hee; Kang, Yoon-Koo
err分享
err收藏
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific病因学对晚期肝细胞癌患者阿特珠单抗联合贝伐单抗疗效结局的影响: 亚太地区的跨国回顾性分析
errTARGETED ONCOLOGY
IF4
err2024-10-03
err0
PREAI
errKim, Sejin; Lee, Suat Ying; Cheon, Jaekyung; Kim, Hyung-Don; Park, Young Gyu; Lee, Joycelyn Jie Xin; Ryu, Min-Hee; Ryoo, Baek-Yeol; Tai, David; Yoo, Changhoon
err分享
err收藏
Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation resultsI期/ Ib期开放标签研究：HER2靶向T细胞接合剂（TCE）SAR443216在晚期实体瘤患者（pts）中的静脉（IV）剂量递增结果
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errMoreno Garcia, V.; Oh, D-Y.; Ryu, M. H.; Calvo, E.; Garralda, E.; Chung, W-P.; Bai, L-Y.; Rojas Laimito, K. I.; Yildirim, O.; Masciari, S.; Mi, G.; Wang, L.; Kanlikilicer, P.; Buday, B.; Rharbaoui, F.; Abbadessa, G.; Dumbrava, E. E.
err分享
err收藏
Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa studyFostrox（fostroxacitabine bralpamide）联合仑伐替尼治疗既往接受免疫联合疗法后进展的局部晚期不可切除或转移性肝细胞癌（HCC）患者：一项多中心 Ib/IIa 期研究的结果
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errChon, H.; Heo, J.; Evans, T. R. J.; Kim, D. Y.; Lim, H. Y.; Macarulla Mercade, T.; Gomez Martin, C.; Moreno Garcia, V.; Ryu, M. H.; Baumann, P.; Bhoi, S.; Jensen, M.; Tunblad, K.; Wallberg, H.; Oberg, F. G.; Reig Monzon, M. E.
err分享
err收藏
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trialNivolumab联合化疗治疗HER2-negative，既往未治疗，不可切除，晚期或复发性胃/胃食管交界癌患者: 吸引-4随机，双盲，安慰剂对照，3期临床试验的3年随访
errGASTRIC CANCER
IF5.1
err2024-08-20
err1
errOAAI
errBoku, Narikazu; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Yamaguchi, Kensei; Kato, Ken; Kadowaki, Shigenori; Tsuji, Kunihiro; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Rha, Sun Young; Lee, Keun-Wook; Chung, Ik-Joo; Sym, Sun Jin; Chen, Li-Tzong; Chen, Jen-Shi; Bai, Li-Yuan; Nakada, Takashi; Hagihara, Shunsuke; Makino, Reina; Nishiyama, Eiji; Kang, Yoon-Koo
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
G
Gad Getz
H 指数: 248 · 论文数: 1.8K
E
Eric Van Cutsem
H 指数: 174 · 论文数: 1.8K
J
Jaffer A. Ajani
H 指数: 152 · 论文数: 1.7K
J
Josep Tabernero
H 指数: 146 · 论文数: 2.7K
A
Andrew D. Cherniack
H 指数: 120 · 论文数: 1.1K
查看更多